- ZEVASKYN is the only FDA-approved therapy to treat RDEB wounds with a single application - ...

Bio-Techne Corporation (NASDAQ: TECH) today announced that its Simple Western Technology played a key role in supporting ...

Bio-Techne Corporation (NASDAQ: TECH) today announced that its Simple Western™ Technology played a key role in ...

In April 2025, prademagene zamikeracel (Zevaskyn, Abeona Therapeutics) became the first FDA-approved cell-based genetic therapy when it was approved for the treatment of wounds in adult and ...

Abeona was awarded the PRV by the U.S. Food and Drug Administration (FDA) in April 2025 in connection with the FDA’s approval of ZEVASKYN™ (prademagene zamikeracel), the first and only U.S ...

Cash resources totaled approximately $225 million as of June 30, 2025CLEVELAND, July 02, 2025 (GLOBE NEWSWIRE) -- Abeona ...

Abeona’s ZEVASKYN™ (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic ...

“Abeona's addition to the Russell 2000 and 3000 indexes, on the heels of ZEVASKYN™'s FDA approval, represents a pivotal moment for the company,” said Joe Vazzano, Chief Financial Officer of ...

The FDA has removed the REMS requirements for existing BCMA- and CD19-directed CAR-T therapies and reduced certain other post-infusion restrictions.

HHS Secretary Robert F. Kennedy Jr. asked the FDA "to review the latest data on mifepristone ," but experts say concerns about the abortion pill's safety are misguided.